The Colorado BioScience Association (CBSA) appointed four new board members at its 2012 Annual All-Member Meeting held at the Westin Westminster, Westminster, CO, yesterday. The announcement is made jointly by Steve Orndorff, Ph.D., Chairperson of the Board of Directors and Holli Riebel, CBSA President & CEO of CBSA.
Newly appointed CBSA board members include:
* James Chomas, Ph.D., Founder & CEO, Surefire Medical - Westminster - www.surefiremedical.com
* Scott Deeter, President & CEO, Ventria Bioscience - Fort Collins - www.ventria.com
* Brent Fassett, Partner, Cooley LLP - Broomfield - www.cooley.com
* Kerry Ingalls, Vice President of Colorado Operations, Amgen - Boulder/Longmont - www.amgen.com
Riebel says: "CBSA’s board is a prestigious group of industry leaders comprised of representatives of biotechnology, medical device, diagnostic, pharmaceutical, health care providers, research institutions and those businesses that provide critical services and products to bioscience companies. Board members commit to a three-year term to support CBSA’s mission to support the regional bioscience community through advocacy, resources and advancement of opportunities for collaboration. CBSA board members work in partnership with staff to support the drive and determination of over 600 Colorado bioscience companies that work to improve lives locally and around the world."
“On behalf of the Board of Directors, I would like to thank the retiring eleven directors for their service and welcome the four new appointees,” Orndorff stated. Special recognition was given to Norwood Robb for serving on the board for ten years. The Executive Officers , in addition to Orndorff, is now instated as Derek Cole, Board Vice Chair, Vice President, Investor Relations & Corporate Communications, ARCA Biopharma; Jim Wilson, Board Treasurer, Senior Audit Manager, Ernst & Young; and John Dunning, Board Secretary, President & CEO, Clarimedix Inc.
Link to the Business Wire Newswire